title: Downstaging of TURBT-Based Muscle-Invasive Bladder Cancer by Radical Cystectomy Predicts Better Survival.
abstract: Differences between clinical (cT) and pathological tumor (pT) stage occur often after radical cystectomy (RC) for muscle-invasive bladder cancer. In order to evaluate the impact of downstaging on recurrence and survival, we selected patients from a large, contemporary, population-based series of 1,409 patients with MIBC. We included all patients who underwent RC (N=643) and excluded patients who received (neo)adjuvant therapy, those with known metastasis at time of diagnosis, and those with nonurothelial cell tumors. Disease outcomes were defined as recurrence-free survival (RFS) and relative survival (RS), as a good approximation of bladder cancer-specific survival. After applying the exclusion criteria, 375 patients were eligible for analysis. Tumor downstaging was found to be common after RC; in 99 patients (26.4%), tumor downstaging to non-muscle-invasive stages at RC occurred. Hydronephrosis at baseline and positive lymph nodes at RC occurred significantly less often in these patients. In 62 patients, no tumor was left in the cystectomy specimen. pT stage was pT1 in 20 patients and pTis in 17 patients. Patients with tumor downstaging have about a 30% higher RFS and RS compared to those without. Consequently, tumor downstaging is a favorable marker for prognosis after RC.
authors.affiliation: Department of Urology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands.
authors.forename: P R
authors.initials: PR
authors.lastname: van Dijk
authors.forename: M
authors.initials: M
authors.lastname: Ploeg
authors.forename: K K H
authors.initials: KK
authors.lastname: Aben
authors.forename: P C
authors.initials: PC
authors.lastname: Weijerman
authors.forename: H F M
authors.initials: HF
authors.lastname: Karthaus
authors.forename: J Th H
authors.initials: JT
authors.lastname: van Berkel
authors.forename: A C
authors.initials: AC
authors.lastname: Viddeleer
authors.forename: A
authors.initials: A
authors.lastname: Geboers
authors.forename: E
authors.initials: E
authors.lastname: van Boven
authors.forename: J A
authors.initials: JA
authors.lastname: Witjes
authors.forename: L A L M
authors.initials: LA
authors.lastname: Kiemeney
references.citation: J Urol. 2009 Aug;182(2):459-65; discussion 465
references.pmid: 19524971
references.citation: Cancer. 2005 Dec 1;104(11):2384-91
references.pmid: 16245327
references.citation: J Urol. 1999 Jul;162(1):74-6
references.pmid: 10379743
references.citation: Urology. 2007 Dec;70(6):1091-5
references.pmid: 18158024
references.citation: Actas Urol Esp. 2009 Sep;33(8):865-8
references.pmid: 19900379
references.citation: Stat Med. 2004 Jan 15;23(1):51-64
references.pmid: 14695639
references.citation: J Clin Oncol. 2001 Jan 1;19(1):89-93
references.pmid: 11134199
references.citation: J Urol. 2006 May;175(5):1645-9; discussion 1649
references.pmid: 16600721
references.citation: J Urol. 1994 Aug;152(2 Pt 1):393-6
references.pmid: 8015078
references.citation: J Urol. 1991 Jan;145(1):45-50
references.pmid: 1984097
references.citation: J Urol. 2003 Oct;170(4 Pt 1):1085-7
references.pmid: 14501697
references.citation: Eur Urol. 2007 Jan;51(1):137-49; discussion 149-51
references.pmid: 16793197
references.citation: Urol Oncol. 2005 Mar-Apr;23(2):77-81
references.pmid: 15869990